Cargando…

The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models

Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mueller, Thomas, Pfankuchen, Daniel Bastian, Wantoch von Rekowski, Kathleen, Schlesinger, Martin, Reipsch, Franziska, Bendas, Gerd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154624/ https://www.ncbi.nlm.nih.gov/pubmed/28467373 http://dx.doi.org/10.3390/molecules22050728

Ejemplares similares

Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway
por: Pfankuchen, Daniel Bastian, et al.
Publicado: (2017)

The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells
por: Wantoch von Rekowski, Kathleen, et al.
Publicado: (2019)

Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies
por: Wantoch von Rekowski, Kathleen, et al.
Publicado: (2020)

The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways
por: Gockel, Lukas Maria, et al.
Publicado: (2018)

Heparin/tinzaparin-sodium: Lack of efficacy: 3 case reports
Publicado: (2020)

Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis
por: Mahmood, Dana, et al.
Publicado: (2010)

Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?
por: Johansen, Kristian B, et al.
Publicado: (2013)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

The Role of Tinzaparin in Oncology
por: Dimakakos, Evangelos P., et al.
Publicado: (2017)

Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review
por: Fioretti, Agnese Maria, et al.
Publicado: (2022)

Tumour cell-activated platelets modulate the immunological activity of CD4(+), CD8(+), and NK cells, which is efficiently antagonized by heparin
por: Gockel, Lukas M., et al.
Publicado: (2022)

Cancer Cell Adhesion and Metastasis: Selectins, Integrins, and the Inhibitory Potential of Heparins
por: Bendas, Gerd, et al.
Publicado: (2012)

Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients
por: Pfrepper, Christian, et al.
Publicado: (2023)

Integrin Activation Contributes to Lower Cisplatin Sensitivity in MV3 Melanoma Cells by Inducing the Wnt Signalling Pathway
por: Piva, Maria B. R., et al.
Publicado: (2017)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation
por: Ponert, Jan Moritz, et al.
Publicado: (2018)

The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer development and metastasis
por: Bendas, Gerd, et al.
Publicado: (2022)

Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells—Deciphering Novel Potential Targets for a Cell Sensitization
por: Jakubzig, Bastian, et al.
Publicado: (2018)

Tinzaparin-sodium: Bleeding and deep venous thrombosis: case report
Publicado: (2022)

Extended-Duration Treatment of Superficial Vein Thrombosis of the Lower Limbs with Tinzaparin
por: Nikolakopoulos, Konstantinos M., et al.
Publicado: (2018)

Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications
por: Helfer, Hélène, et al.
Publicado: (2019)

Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review
por: Vathiotis, I. A., et al.
Publicado: (2021)

Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study
por: Akinosoglou, Karolina, et al.
Publicado: (2022)

The molecular mechanism by which saturated lysophosphatidylcholine attenuates the metastatic capacity of melanoma cells
por: Ross, Thomas, et al.
Publicado: (2016)

Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
por: Heo, Eun Jin, et al.
Publicado: (2017)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Single-Bolus Tinzaparin Anticoagulation in Extended Hemodialysis Session: A Feasibility Study
por: Harvey, Benoît, et al.
Publicado: (2023)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
por: Reipsch, Franziska, et al.
Publicado: (2021)

A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
por: König, Philipp, et al.
Publicado: (2023)

Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies
por: Kleinmanns, Katrin, et al.
Publicado: (2022)

A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells
por: Haschemi, Reza, et al.
Publicado: (2021)

Spontaneous gall bladder haemorrhage in a renal dialysis patient following haemodialysis with tinzaparin
por: Borman, Natalie, et al.
Publicado: (2010)

Tinzaparin—a review of its molecular profile, pharmacology, special properties, and clinical uses
por: Amerali, Marina, et al.
Publicado: (2022)

Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts
por: Li, Wei, et al.
Publicado: (2014)

Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β(1)-Integrin Emerges as a Key Factor for Breast Cancer Chemosensitization upon Collagen Type 1 Binding
por: Baltes, Fabian, et al.
Publicado: (2020)

Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer
por: Sarantis, Panagiotis, et al.
Publicado: (2021)

Patient-Derived Xenografts Are a Reliable Preclinical Model for the Personalized Treatment of Epithelial Ovarian Cancer
por: Chen, Jiayu, et al.
Publicado: (2021)

Tinzaparin Provides Lower Lipid Profiles in Maintenance Hemodialysis Patients: A Cross-Sectional Observational Study
por: Tsai, Ming-Hsien, et al.
Publicado: (2014)

Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis
por: Martínez-Zapata, M. José, et al.
Publicado: (2017)

The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study
por: Karamouzis, Michalis V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vs8g0cfujj06stbkogefeo6460